Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glutamate-rich protein 5 (ERICH5) is encoded by the ERICH5 gene on human chromosome 8q22.2 and contains three exons[2][7]. The protein is predicted to localize to the nucleus, contains a conserved domain of unknown function (DUF4573), and has motifs linked to APC/C binding and nuclear cell checkpoint processes[2]. ERICH5 exists in two isoforms, interacts with several nuclear proteins, and is expressed most highly in the fetal liver, adult liver, pancreas, and retina[2][1][5][6]. It shows increased expression in Alcoholic Hepatitis but no substantial evidence for a therapeutic target role or direct involvement in major human diseases[2][5]. No drugs, biomarkers, or safety concerns have been identified in relation to this gene/protein to date.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate-rich protein 5 (ERICH5).